This article presents an evaluation of testosterone marketing practices around the period of the testosterone label warning by physician specialty and rural vs urban primary care service area.
Ashwini Sankar, PhD
Advertisement
Articles by Ashwini Sankar, PhD
Advertisement
Latest Updated Articles
- FDA Safety Warnings and Trends in Testosterone Marketing to Physicians
Published: March 7th 2022 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Tirzepatide Plus Hormone Therapy Boosts Weight Loss in Menopause: Regina Castaneda, MD
2
FDA Approves Elinzanetant, a Hormone-Free Option for Hot Flashes in Menopause
3
GLP-1 Receptor Agonists May Improve Rheumatoid Arthritis Symptoms
4
Elinzanetant Shows Strong 52-Week Safety for Vasomotor Symptoms: James Simon, MD
5
